Arterial dysfunction in syndrome X: results of arterial reactivity and pulse wave propagation tests

M Kidawa, M Krzeminska-Pakula, J Z Peruga, J D Kasprzak

Objective: To assess arterial distensibility using pulse wave velocity (PWV) measurements and its relation with endothelium dependent vasodilatation (EDV) in patients with cardiological syndrome X.

Methods: The study group consisted of 92 patients: 52 with syndrome X (34 women, 18 men, mean (SD) age 45 (3) years) and 40 healthy volunteer controls (27 women, 13 men, mean (SD) age 41 (2) years) without risk factors of atherosclerosis and with negative ECG exercise test and normal proximal coronary arteries on transoesophageal echocardiography. Patients with arterial hypertension, diabetes mellitus, valvar disease, or cardiomyopathy were excluded. PWV was calculated for each patient. EDV was assessed from two dimensional Doppler measurement using an Acuson Sequoia with 8 MHz linear transducer at rest, during postischaemic reactive hyperaemia, and after an oral dose of 400 µg of glyceryl trinitrate.

Results: PWV was significantly higher in patients with syndrome X than in healthy subjects (9.3 (0.7) m/s v 8.2 (0.9) m/s, respectively, p < 0.001). Baseline brachial artery diameter varied similarly in the syndrome X and control groups (4.0 (0.6) mm v 4.08 (0.64) mm, NS). EDV was impaired in patients with syndrome X compared with controls [6.6 (3.0)% v 11.1 (3.9)%], p < 0.001]. Endothelium independent vasodilatation was similar in both groups. In patients with syndrome X there was a positive correlation between PWV and the degree of EDV (r = 0.864, p < 0.001). The cut off value for PWV was 8.5 m/s, with a sensitivity of 62% and a specificity of 91%.

Conclusions: EDV but not glyceryl trinitrate induced vasodilatation is decreased in patients with syndrome X. There is a strong correlation between PWV and the degree of endothelial dysfunction of peripheral arteries in patients with syndrome X. PWV assessment may be useful to identify abnormal vascular physiology in these patients.

METHODS

Patient population

The study population consisted of 52 patients with angina, without prior myocardial infarction (mean (SD) age 45 (3) years, 34 women, 18 men) who underwent coronary angiography in our cardiology department during 1998 and 1999. They fulfilled the characteristic criteria for the diagnosis of syndrome X: angina-like chest pains, positive ECG exercise test, normal coronary arteries on angiography, and no metabolic disorders.

Exclusion criteria were a previous diagnosis of dilated or constrictive cardiomyopathy, a previous myocardial infarction.

Abbreviations: EDV, endothelium dependent vasodilatation; GTN, glyceryl trinitrate; PWV, pulse wave velocity
arterial hypertension, metabolic disorders such as diabetes mellitus, dyslipidaemia, and insulin resistance syndrome, ECG conductivity and rhythm disorders, valvar heart disease, Barlow’s syndrome, or any other known functional peripheral arterial disorders. None of our patients was treated at the time of syndrome X using the standard Judkins technique on a General Electric Advantax LX system (Acuson, Mountain View, California, USA) according to the protocol described by Fathi and colleagues and Celermajer and associates. The right brachial artery was scanned at rest, during reactive hyperaemia, and after administration of sublingual glyceryl trinitrate (GTN). Before the first scan the patient rested in the supine position for at least 10 minutes. Then the brachial artery diameter and blood flow velocity were measured. Blood flow was measured from the pulsed Doppler signal at a maximum incidence angle of 60°, with the Doppler gate positioned in the middle of the arterial lumen. Reactive hyperaemia was induced with inflation of a pneumatic tourniquet to a pressure of 200 mm Hg for five minutes. The artery diameter was measured 45–60 seconds after cuff deflation and flow velocity recordings were started 15 seconds after cuff release. After 15 minutes an additional baseline scan was recorded and then four minutes after 400 µg sublingual GTN was given, the last images were collected. ECG monitoring was continuous during the procedure, and ECG R wave measurements were averaged from four consecutive beats. Arterial diameters were measured from the anterior to the posterior “m” line at the end of diastole. All measurements were taken by two observers who were unaware of clinical details. The previously estimated mean (SD) inter-sonographer variability of flow mediated dilatation measurement in our echocardiography laboratory was 1.2 (0.4)%.

Vasodilatation was expressed as the percentage increase in artery diameter during reactive hyperaemia (EDV) and after GTN administration (endothelium independent vasodilatation). Reactive hyperaemia was calculated as the maximum flow over the 15 seconds after cuff release divided by the baseline flow values (fig 1).

PWV was measured automatically with a Complior Colson device based on an IBM Aptiva 486 DX personal computer according to the methods described by Asmar and colleagues. PWV was calculated from measurements of the pulse transit time between two recording sites, the femoral and carotid external arteries, at a sampling frequency of 500 Hz. During preprocessing analysis the gain of each waveform was adjusted to obtain an equal signal for the two waveforms. During PWV measurements, after pulse waveforms of sufficient quality were recorded, the digitisation process was initiated by the operator and automatic calculation of the time delay between two upstrokes was started (fig 2). The interobserver repeatability (repeatability coefficient) for the automatic PWV calculation in our laboratory was 0.876 (95% confidence interval ± 1.95 repeatability coefficient).

Statistical analysis was performed with the Statistica 5.0 data analysis program using non-parametrical U Mann-Whitney tests. Correlations were calculated with the Spearman test. All results are expressed as mean (SD).

The investigation conforms with the principles outlined in the Declaration of Helsinki.
RESULTS

Table 1 shows demographic and biochemical data. Because of the enrolment criteria, patients in the control group were younger than those in the syndrome X group (mean (SD) 41 (2) years vs 45 (3) years, respectively) to minimise the risk for silent coronary disease.

Blood analysis showed significantly higher plasma concentrations of total cholesterol, low density lipoprotein fraction, and triglycerides in the syndrome X population than in controls. High density lipoprotein concentrations were much lower in the syndrome X group. However, all of these values were within the normal ranges (table 1).

ECG exercise tests were positive only in patients with syndrome X. In the syndrome X group, baseline heart rate was significantly higher and total exercise phase was significantly shorter than in the controls (table 1). In 29 patients with syndrome X, chest pain occurred during the test at a mean (SD) exercise time of 4.9 (1) minutes.

Echocardiographic examination confirmed that both groups had normal cardiac size and function with clinically insignificant differences between the groups. The ejection fraction was slightly lower in patients with syndrome X than in the control group.

Arterial vasodilator tests

Under baseline conditions there were no significant differences in measurements of brachial artery diameter (4.0 (0.6) mm vs 4.08 (0.64) mm, NS) and baseline blood flow velocities (74.1 (14.2) cm/s vs 73 (13.9) cm/s, NS) between the syndrome X and control groups, respectively. After oral administration of GTN the mean increase in blood flow velocity and in arterial diameter was similar in both groups and there was no significant difference in endothelium independent vasodilatation (mean (SD) percentage arterial diameter increase 18.1 (5.1)% vs 19.6 (5.1)%, NS).

After the induction of reactive hyperaemia the mean (SD) increase in arterial diameter was significantly lower in patients with syndrome X than in controls (0.27 (0.12) mm vs 0.44 (0.16) mm, respectively), which showed that EDV was significantly impaired in patients with syndrome X (6.6 (3.0)% vs 11.1 (3.9)% in controls, p < 0.001) (fig 3).

During hyperaemia the increase in blood flow velocity was similar in the syndrome X and control groups.

PWV measurements

In the syndrome X group pulse wave propagation time between measurement sites was significantly shorter than in the control group (65.1 (6.2) ms vs 76.1 (8.2) ms, respectively, p < 0.001).

Comparing with the syndrome X group, PWV values were significantly lower in controls (9.3 (0.7) m/s vs 8.2 (0.9) m/s, p < 0.001), as fig 4 shows.

A PWV of 8.5 m/s allows for differentiation between groups with a sensitivity of 62% and a specificity of 91%.

Further analysis showed the presence of a strong inverse correlation between PWV and EDV (fig 5). The regression equation is PWV = 15.07 − 0.75 × EDV, Pearson’s r = −0.864, p < 0.01.

In our study we did not find any significant correlation between PWV and age, sex, or mean blood pressure in the studied groups.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Syndrome X group</th>
<th>Control group</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>52</td>
<td>40</td>
<td>NS</td>
</tr>
<tr>
<td>Women</td>
<td>34</td>
<td>27</td>
<td>NS</td>
</tr>
<tr>
<td>Average age (years)</td>
<td>45 (3)</td>
<td>41 (2)</td>
<td>0.01</td>
</tr>
<tr>
<td>Smokers</td>
<td>3</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>Positive family history for IHD</td>
<td>5</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>124.7 (7.9)</td>
<td>124.8 (7.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>77.1 (6.3)</td>
<td>77.1 (6.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.72 (0.19)</td>
<td>4.68 (0.22)</td>
<td>NS</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>2.72 (0.32)</td>
<td>2.71 (0.33)</td>
<td>NS</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.52 (0.14)</td>
<td>1.53 (0.15)</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides (g/l)</td>
<td>1.04 (0.12)</td>
<td>1.01 (0.13)</td>
<td>NS</td>
</tr>
<tr>
<td>Resting heart rate (beats/min)</td>
<td>75.6 (7.8)</td>
<td>71.0 (6.7)</td>
<td>0.01</td>
</tr>
<tr>
<td>Maximum heart rate (beats/min)</td>
<td>151 (10)</td>
<td>146 (12)</td>
<td>0.01</td>
</tr>
<tr>
<td>Maximum ST depression (mm)</td>
<td>2.4 (0.4)</td>
<td>0.9 (0.4)</td>
<td>0.01</td>
</tr>
<tr>
<td>Exercise test duration (min)</td>
<td>6.8 (1.8)</td>
<td>9 (0.9)</td>
<td>0.01</td>
</tr>
<tr>
<td>Ischaemic pain present (number)</td>
<td>29</td>
<td>0</td>
<td>NA</td>
</tr>
</tbody>
</table>

Values are mean (SD). HDL, high density lipoprotein; IHD, ischaemic heart disease; LDL, low density lipoprotein; NA, not applicable; NS, not significant.

Figure 3 Comparison of mean increase in brachial artery diameter after reactive hyperaemia between the syndrome X and control groups.

Figure 4 Mean (SD) pulse wave velocity (m/s) measurements in the study groups.
Arterial dysfunction in syndrome X

DISCUSSION

Our study showed two main abnormalities in peripheral arterial function in patients with syndrome X: impaired EDV and increased PWV. The response to nitrates was not altered, indicating that endothelium independent vasodilatation is not impaired in patients with syndrome X.

In previous studies reduced acetylcholine induced vasodilatation of coronary arteries in syndrome X was reported. Endothelial dysfunction in coronary arteries may lead to reduction in arterial flow reserve and induce ischaemic pain in syndrome X. This theory may be supported by the results of endothelium vasodilator tests performed with intracoronary acetylcholine infusions, which showed an abnormal constriction reaction especially in sites with increased risk for development of atherosclerosis such as proximal parts or bifurcation of the arteries in patients with syndrome X. In studies performed by Celermaier and colleagues, they observed a strong correlation between atherosclerotic risk factors and the degree of generalised arterial dysfunction in these patients. PWV measurements provide highly reproducible estimates of arterial distensibility, particularly with the automated method proposed by Asmar and colleagues. Some studies suggest that the PWV increase may be used as an early indicator of atherosclerosis development, and a significant decrease in compliance in large arteries was found in patients with atherosclerosis risk factors such as heterozygous familial hypercholesterolaemia.

A significant correlation between increased arterial stiffness and atherosclerosis formation was described. In some studies, however, hypertension was shown to influence arterial rigidity more than atherosclerotic risk factors. All patients selected for our study were normotensive so as to minimise the effect of arterial remodelling caused by increased arterial pressure.

EDV impairment in our patients with syndrome X was closely correlated with PWV values. Our results indicating impairment of endothelial function and increased arterial distensibility may support the theory that the vascular abnormalities in syndrome X are a generalised process similar to those observed in the early stages of atherosclerosis.

Study limitations

We did not undertake an intravascular ultrasound examination, the ultimate means of visualising coronary vascular anatomy. However, our intention was to test non-invasive techniques for analysing the function of systemic arteries in syndrome X. Even with intravascular ultrasound technology, subtle anatomical abnormalities in distal parts of the coronary arteries may be undetectable. The age difference between groups may also have influenced our results, but we did not find a correlation between PWV and age in the studied patient populations, nor any correlation between endothelial function and age.

The results of our study do not provide firm evidence that there is a direct link between increased PWV and myocardial perfusion impairment in syndrome X, although the presence of a correlation between PWV and the degree of endothelial dysfunction may indicate such a relation. The cut off value of PWV was measured retrospectively and further prospective studies should be performed to investigate the usefulness of this parameter in identifying patients with syndrome X.

Conclusions

EDV is impaired in peripheral arteries of patients with syndrome X, and a significant rise in PWV reflects the increased arterial wall stiffness in such patients. A strong inverse correlation between PWV and EDV may indicate generalised arterial dysfunction in these patients. PWV measurements may be useful in differentiating patients with syndrome X from healthy subjects.

Authors’ affiliations

M Kidawa, M Krezminska-Pakula, J Z Peruga, J D Kasprzak, Department of Cardiology, Medical University of Lodz, Bieganski Hospital, Lodz, Poland

REFERENCES


Figure 5 Correlation between pulse wave velocity (PWV) and endothelium dependent vasodilatation (EDV), where PWV = 15.07 – 0.75 × EDV, Pearson’s r = −0.864, p<0.01.
endothelial function in the human coronary and peripheral circulations.

-dependent coronary vasodilatation in patients with angina pectoris and having coronary artery disease.

carotid artery in predicting coronary narrowing in patients suspected of dilatation of the brachial artery and/or the intima-media thickness of the endothelium-dependent dilatation of the brachial arteries is impaired in
coronary angiograms.

in coronary resistance vessels in patients with angina pectoris and normal endothelial dysfunction in patients with angina pectoris and normal coronary angiograms.

syndrome X.


endothelial dysfunction in patients with angina pectoris and normal coronary angiograms.

endothelium-dependent dilatation in children and adults at risk of atherosclerosis.


Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. Am J Cardiol 2001;88:1147–51.

Dysfunction of large arteries. Circulation 1999;100:231–8. (Education in Heart)


3 In-stent stenosis: pathology and implications for the development of drug eluting stents. MB Bennett February 2003;89:218–24. (Education in Heart)


Assessment of myocardial viability: using coronary pressure and flow after acute myocardial infarction. MJ Kern January 2003;89:9–10. (Commentary)

Visit the Heart website for hyperlinks to these articles, by clicking on “Top 10 papers”.

www.heartnl.com